Opendata, web and dolomites


Unveiling the signature of transposable elements-derived transcripts – the transposcriptome – as a biomarker in human acute myeloid leukemia

Total Cost €


EC-Contrib. €






 LEUKEMIC-TEs project word cloud

Explore the words cloud of the LEUKEMIC-TEs project. It provides you a very rough idea of what is the project "LEUKEMIC-TEs" about.

epigenetics    gene    frequent    demonstrated    bridge    lack    proper    basis    acute    leukemias    industry    ideal    homology    therapies    mediocre    academy    collaborations    create    genome    malignant    provides    expression    tool    lsc    categorization    technologies    transposable    linked    skills    denser    patients    existence    human    samples    te    progenitors    networks    explained    decisive    scientific    treat    cell    achievement    pipelines    unexplored    relapsed    tes    cells    biomarkers    thirds    researcher    throughput    adults    directed    largely    limited    exclusive    chromosomes    science    difficult    immunotherapeutically    pluripotency    aml    stem    myeloid    excellence    tumorigenic    normal    regulation    leukemia    aberrant    complementary    transcriptome    background    oncoproteins    advent    hematopoietic    soft    tumorigenesis    cd34cd38    characterization    cancer    subclassification    signature    thought    reprogramming    roles    outcome    fractions    analytical    invaluable    accomplishment    solely    coverage    identification    sequencing    precursors   

Project "LEUKEMIC-TEs" data sheet

The following table provides information about the project.


Organization address
address: BATIMENT CE 3316 STATION 1
postcode: 1015

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website
 Total cost 175˙419 €
 EC max contribution 175˙419 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2017
 Duration (year-month-day) from 2017-04-01   to  2019-03-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 


 Project objective

Acute myeloid leukemia (AML) is the most common of the acute leukemias among adults. Relapsed AML patients are frequent but difficult to treat since effective therapies are limited. This mediocre outcome can be partially explained by the presence of leukemia stem cells (LSC) that maintain an aberrant hematopoietic process. LSC in AML were traditionally thought to be solely CD34CD38- cells. However, recent studies demonstrated the presence of LSC in cell fractions thought to be non-tumorigenic. Finding an LSC-specific signature would be decisive for a better categorization of patients and LSC exclusive targeting. This project considers the signature of transposable elements (TEs) as an ideal tool for the identification of LSC. TEs, with important roles in gene regulation, are linked to the reprogramming process to pluripotency and they are associated with tumorigenesis. Since they contribute up to two thirds of the human genome, TEs expression provides much denser coverage of chromosomes than gene-derived transcriptome. TEs signature in cancer has so far been largely unexplored per lack of proper technologies. The advent of high-throughput sequencing and the development of TE-directed analytical pipelines allow now the accomplishment of this project. The present proposal includes a comprehensive characterization of TEs transcriptome in normal and malignant hematopoietic precursors. An expected result is the achievement of a better subclassification of AML samples on the basis of their TEs expression homology to normal progenitors. The project will investigate the existence of TE-derived oncoproteins exclusive for LSC that could be immunotherapeutically targeted. This proposal has impact on the excellence of European science since it will create new collaborations and networks to find AML biomarkers. It would bridge academy with industry and will bring invaluable complementary scientific and soft skills to a researcher with an ideal background in cancer epigenetics.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LEUKEMIC-TES" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LEUKEMIC-TES" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

STIMOS (2019)

Stimulation of Multiple Organoids Simultaneously

Read More  


An integrated hypothesis for cognitive and positive symptoms in schizophrenia

Read More  

GWFP (2019)

Geometric study of Wasserstein spaces and free probability

Read More